Pharmachem Laboratories, Inc.
http://www.pharmachemlabs.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Pharmachem Laboratories, Inc.
Xbrane Inching Closer To Cimzia Biosimilar Trials With Batch Production
Sweden’s Xbrane Biopharma has delivered updates for two of its more long-term projects, including a proposed biosimilar to Bristol Myers Squibb’s Opdivo for which it is actively seeking a partner.
Flagship Plans To Distribute New Fund To About Two Dozen Companies
The venture capital firm announced a $3.6bn raise for Fund VIII and side funds, which it plans to invest across human health, AI and sustainability-focused companies.
Xbrane Working Towards Q2 2025 US Ranibizumab Approval
Xbrane plans to refile its proposed biosimilar to Lucentis by the end of 2024, after the recent disappointment of a US FDA complete response letter. However, the goal requires its manufacturing partners to successfully execute remediation plans.
‘Keytruda? We Believe Opdivo Is The Better Choice’: Xbrane’s CEO Martin Åmark
The CEO of Xbrane Biopharma, a Swedish firm focused solely on biosimilar development using a partnered model to potentially take its biosimilars across the globe, speaks exclusively to Generics Bulletin about its ambitions and challenges, including the recent setback for its proposed Lucentis biosimilar in the US.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Nutraceuticals
- Other Names / Subsidiaries
-
- Forbes Medi-Tech, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice